Management Strategies After Osimertinib Progression in EGFR‑Mutant NSCLC

1. Initial Assessment and Progression Pattern

• Perform tissue re‑biopsy (preferred) or liquid biopsy with next‑generation sequencing to identify the resistance mechanism, which will guide the choice of targeted therapy, chemotherapy, or local ablative approaches. 1, 2
• Oligoprogression (1–3 sites): continue osimertinib at the standard dose and add local ablative therapy (surgery, stereotactic body radiation therapy, or radiofrequency ablation) to the progressing lesions. (Category 1 recommendation) 1, 2
• Isolated CNS oligoprogression: treat the brain lesion(s) with stereotactic radiosurgery while maintaining osimertinib. 1
• Leptomeningeal disease or non‑SRS candidates with symptomatic CNS involvement: consider whole‑brain radiotherapy and continue osimertinib. 1
• Slow/indolent progression (asymptomatic, RECIST‑defined radiological progression between stable disease and progressive disease): maintain osimertinib 80 mg daily. 1, 3
• Optional dose escalation to 160 mg daily may be used in selected patients, but it is not a standard of care. 1
• Symptomatic systemic progression with multiple lesions: discontinue osimertinib and proceed immediately to molecular profiling to determine the next line of therapy. 1, 2

2. Molecular Profiling and Resistance Mechanisms

• Comprehensive NGS (tissue preferred) identifies four major resistance patterns:

  • MET amplification – observed in 15–30 % of cases.
  • Histologic transformation – occurs in 12–15 % of cases.
  • On‑target EGFR alterations (e.g., C797S) – seen in 10–20 % of cases.
  • No targetable mechanism – present in 40–50 % of cases.
    All percentages are derived from pooled analyses of post‑osimertinib biopsies. 1

• MET amplification: the preferred regimen is amivantamab combined with carboplatin and pemetrexed (Category 1 recommendation). 1, 2

• Histologic transformation:

  • Small‑cell transformation – treat with carboplatin + etoposide; the role of concurrent osimertinib remains investigational. (Level II evidence) 1, 3
  • Squamous transformation – apply histology‑appropriate chemotherapy for squamous cell carcinoma. (Level II) 3
  • Small‑cell transformation can only be confirmed on tissue biopsy; liquid biopsy is insufficient. 1, 2

• On‑target EGFR alterations (e.g., C797S): no approved targeted agents; patients should be enrolled in clinical trials of next‑generation EGFR inhibitors. (Level III) 1

• No targetable mechanism: standard treatment is platinum‑based doublet chemotherapy ± bevacizumab, yielding an objective response rate of ≈30 % and median PFS of 5–6 months. (Level I) 4, 3

3. Treatment Strategies per Resistance Mechanism

4. Immunotherapy Considerations and Pitfalls

• Immune‑checkpoint inhibitor (ICI) monotherapy is ineffective in EGFR‑mutant NSCLC, with response rates of only 3.6 % versus 23 % in EGFR‑wild‑type disease, irrespective of PD‑L1 status. (Level I) 5, 6
• Avoid administering osimertinib within 3 months of an ICI because the combination is associated with a high incidence of pneumonitis (~38 %). (Level I) 6
• Do not continue osimertinib together with chemotherapy at progression. Data from the IMPRESS trial (first‑generation EGFR TKIs) showed no PFS or OS benefit, and extrapolation suggests the same for osimertinib. (Level I) 6, 4

5. EGFR‑TKI Rechallenge

• Rechallenge with osimertinib can be considered when the patient has been off any EGFR TKI for ≥ 6 months, no targetable resistance mechanism is identified, and the progression is limited (e.g., isolated CNS disease). (Level III, Grade C) 5, 6, 4
• Rechallenge dosing: standard 80 mg daily. (Level III) 5, 6

6. Clinical‑Trial Prioritization

• When molecular profiling reveals a resistance mechanism without an approved targeted therapy (e.g., on‑target EGFR alterations), enrollment in a relevant clinical trial should be the preferred option. (Level II) 1, 3

7. Algorithmic Summary (Key Decision Points)

• Oligoprogression → local ablative therapy + continue osimertinib.
• Slow/indolent progression → continue osimertinib.
• Systemic symptomatic progression → stop osimertinib. (Citation 3)

Next-Line Systemic Treatment for Metastatic Lung Adenocarcinoma with Brain Metastases

Primary Treatment Recommendation

• The American Society of Clinical Oncology recommends amivantamab plus carboplatin and pemetrexed as the preferred next-line treatment for patients with metastatic lung adenocarcinoma harboring EGFR exon 19 deletion and acquired MET amplification who have progressed on osimertinib, with a Category 1 recommendation for symptomatic systemic progression with multiple lesions 7, 8
• This combination achieves a median PFS of 6.3 months versus 4.2 months with chemotherapy alone, and an objective response rate of 64% versus 36% with chemotherapy alone 8

Critical Importance of MET Amplification

• The European Society for Medical Oncology guidelines state that acquired MET amplification is one of the two most actionable findings on repeat biopsy, and may be treated with a combination of an EGFR and a MET TKI 9, 10

Treatment Algorithm

• The European Society for Medical Oncology recommends performing tissue rebiopsy or liquid biopsy to confirm MET amplification and rule out other resistance mechanisms 9, 10
• For symptomatic systemic progression with multiple lesions, the American Society of Clinical Oncology recommends initiating amivantamab plus carboplatin and pemetrexed 7, 8

Alternative Considerations

• If amivantamab is not available, platinum-based chemotherapy is recommended as the standard second-line option following osimertinib progression 7

Critical Pitfalls to Avoid

• The American Society of Clinical Oncology advises against using PD-1/PD-L1 inhibitors in EGFR-mutant NSCLC, as they show inferior efficacy regardless of PD-L1 expression 8
• The European Society for Medical Oncology advises against using osimertinib within 3 months of immune checkpoint inhibitors due to significantly increased risk of pneumonitis 8, 11

Monitoring During Treatment

• The American Society of Clinical Oncology recommends CT imaging every 6-12 weeks to assess response, and brain MRI at each follow-up given baseline CNS involvement 9, 11